Health insurance company Cigna (NYSE: CI) reported Q3 2026 results topping the market’s revenue expectations, with sales up 6.1% year on year to $73.79 billion. Its non-GAAP profit of $7.98 per share was 6.3% above analysts’ consensus estimates.

Is now the time to buy CI? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Cigna’s third quarter results received a positive market response, reflecting both operational execution and strategic decisions across its core businesses. Management attributed the quarter’s performance to strong growth in specialty pharmacy, disciplined pricing in its health insurance segment, and continued expansion in care services. CEO Brian Evanko noted that Cigna’s specialty and care businesses “delivered attractive performance, including pre-tax adjusted earnings growth of 15% year-over-year,” largely driven by biosimilar and generic adoption rates and expanded distribution capabilities. The company also highlighted the benefits of investment income and recent product launches in customer engagement.

Looking ahead, management emphasized the importance of the Lead to One strategy, which focuses on delivering personalized care at scale by integrating medical, pharmacy, behavioral health, and specialty care for complex patient needs. CEO Brian Evanko stated that this approach “positions us to build momentum in 2027,” while CFO Ann Dennison pointed to the Accelerate to One cost initiative, targeting $3 billion in gross savings by 2030. However, leaders also flagged headwinds such as lower new biosimilar launches, industry-wide pressure on gross rebates, and their planned exit from the ACA exchange business, which will impact near-term revenue and margins.

Key insights from management’s remarks

Management identified specialty pharmacy expansion, disciplined pricing in health insurance, and the early impact of new product initiatives as main drivers of quarterly performance, while also outlining key cost and regulatory challenges.

• Specialty pharmacy momentum: The specialty and care services segment reported significant growth, attributed to increased adoption of biosimilars and generics, as well as manufacturer partnerships enabling access to exclusive and limited distribution drugs. Management cited Accredo’s access to over 330 complex products and the construction of a fifth clean room as evidence of its infrastructure investment.

• Pharmacy benefit model transition: The rollout of the new Signature pharmacy benefits model, designed to simplify pricing and improve affordability, progressed through its design and initial implementation phases. Early client interest and regulatory alignment were highlighted, with broader adoption expected in 2028. Management emphasized that Signature’s focus on transparency and lowest out-of-pocket costs aligns with evolving government regulations.

• Health insurance segment execution: The Cigna Healthcare business achieved margin improvement and medical cost stability through disciplined pricing strategies and advanced analytics. The company’s Select segment, serving smaller employers, saw continued customer growth, indicating market share gains.

• Technology and customer engagement: Cigna launched Health Sense, a data- and technology-driven solution aimed initially at oncology patients. The platform connects customers’ health needs, benefits, and prior claims to enable earlier interventions, with management noting strong early reception and a plan to expand beyond oncology.

• Cost containment and modernization: The Accelerate to One initiative, targeting $3 billion in gross savings by 2030, is underway, focusing on automation, vendor management, and workforce effectiveness. Management stated that a portion of these savings will be reinvested to fund growth and support long-term earnings growth targets.

Drivers of future performance

Cigna’s forward guidance is shaped by ongoing specialty pharmacy performance, cost savings initiatives, and evolving regulatory and product trends.

• Specialty pharmacy and biosimilar pipeline: Management expects continued growth in specialty and care services, though at the lower end of its long-term target due to a limited pipeline of new biosimilar and specialty generic launches in 2027. This temporary slowdown is anticipated to be offset in later years as more biosimilars for complex conditions reach the market.

• Costs and productivity initiatives: The Accelerate to One program will reduce Cigna’s cost base through automation, process modernization, and vendor rationalization. While $3 billion in gross savings are targeted by 2030, management explained that not all savings will reach the bottom line, as some will be used to fund innovation and business reinvestment.

• Regulatory and market transitions: The exit from the ACA exchange business and regulatory changes affecting pharmacy benefit management are expected to create near-term headwinds. Lower employer coverage of GLP-1 weight loss drugs and industry-wide rebate compression will also pressure the Evernorth division’s income in 2027, though management sees these as transitional issues as new product models are adopted.

Catalysts in upcoming quarters

In the coming quarters, the StockStory team will be watching (1) how quickly the Signature pharmacy benefit model is adopted and its effect on client retention and profitability, (2) the progress and impact of the Accelerate to One cost savings initiative, and (3) the pace of biosimilar and specialty generic launches in the specialty pharmacy division. Developments in regulatory compliance and the company’s response to ACA exchange exit costs will also serve as important signposts.

Cigna currently trades at $301.40, down from $305.41 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).

High quality stocks for all market conditions

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.